Table 2. Nanoparticle-based gene therapy under clinical evaluation.
| Delivery system | Product | Sponsor | Disease | Administration | Phase | Status | Gov identifier |
|---|---|---|---|---|---|---|---|
| PEI-based nanoparticles | BC-819/PEI | BioCancell | BC | Local | 2 | Active | NCT00595088 |
| BC-819 | BioCancell | OC | IP | 1/2 | Completed | NCT00826150 | |
| DTA-H19 | BioCancell | PN | Local | 1/2 | Completed | NCT00711997 | |
| EGEN-001 | Gynecologic Oncology Group | Cancer | IP | 2 | Active | NCT01118052 | |
| Lipid-based nanoparticles | TKM-080301 | National Cancer Institute | HM | IA | 1 | Completed | NCT01437007 |
| TKM-080301 | Tekmira Pharmaceuticals Corporation | HC | IV | 1/2 | Recruiting | NCT02191878 | |
| TKM-080301 | Tekmira Pharmaceuticals Corporation | NET; ACC | IV | 1/2 | Completed | NCT01262235 | |
| Atu027 | Silence Therapeutics GmbH | ASC | IV | 1 | Completed | NCT00938574 | |
| ALN-TTR02 | Alnylam Pharmaceuticals | TTR-A | IV | 2 | Completed | NCT01617967 | |
| DOTAP-Chol-fus1 | MD Anderson Cancer Center | LC | IV | 1 | Completed | NCT00059605 | |
| DCR-MYC | Dicerna Pharmaceuticals | ST; MM; NHL | IV | 1 | Recruiting | NCT02110563 | |
| DCR-MYC | Dicerna Pharmaceuticals | HC | IV | 1/2 | Recruiting | NCT02314052 | |
| ND-L02-s0201 Injection | Nitto Denko Corporation | EHF | IV | 1 | Recruiting | NCT02227459 | |
| PLGA-based nanoparticles | siG12D LODER | Silenseed | PC | Local | 2 | Active | NCT01676259 |
ACC, adrenocortical carcinoma; ASC, advanced solid cancer; BC, bladder cancer; EHF, extensive hepatic fibrosis; HC, hepatocellular carcinoma; HM, hepatic metastases; IA, intra-arterial; LC, lung cancer; MM, multiple myeloma; NET, neuroendocrine tumors; NHL, non-Hodgkins lymphoma; OC, ovarian cancer; PC,pancreatic cancer; PEI, polyethylenimine; PLGA, poly(lactic-co-glycolic acid); PN, pancreatic neoplasms; ST, solid tumors; TTR-A, transthyretin amyloidosis.